Literature DB >> 2458208

Sublingual absorption of selected opioid analgesics.

D S Weinberg1, C E Inturrisi, B Reidenberg, D E Moulin, T J Nip, S Wallenstein, R W Houde, K M Foley.   

Abstract

Ongoing interest in the improvement of pain management with opioid analgesics had led to the investigation of sublingual opioid absorption. The present report determined the percent absorption of selected opioid analgesics from the oral cavity of normal subjects under conditions of controlled pH and swallowing when a 1.0 ml aliquot of the test drug was placed under the tongue for a 10-minute period. Compared with morphine sulfate at pH 6.5 (18% absorption), buprenorphine (55%), fentanyl (51%), and methadone (34%) were absorbed to a significantly greater extent (p less than 0.05), whereas levorphanol, hydromorphone, oxycodone, heroin, and the opioid antagonist naloxone were not. Overall, lipophilic drugs were better absorbed than were hydrophilic drugs. Plasma morphine concentration-time profiles indicate that the apparent sublingual bioavailability of morphine is only 9.0% +/- 11.9% (SD) of that after intramuscular administration. In the same subjects the estimated sublingual absorption was 22.4% +/- 9.2% (SD), indicating that the sublingual absorption method may overestimate apparent bioavailability. When the oral cavity was buffered to pH 8.5, methadone absorption was increased to 75%. Thus, an alkaline pH microenvironment that favors the unionized fraction of opioids increased sublingual drug absorption. Although absorption was found to be independent of drug concentration, it was contact time dependent for methadone and fentanyl but not for buprenorphine. These results indicate that although the sublingual absorption and apparent sublingual bioavailability of morphine are poor, the sublingual absorption of methadone, fentanyl, and buprenorphine under controlled conditions is relatively high.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458208     DOI: 10.1038/clpt.1988.159

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  45 in total

1.  Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.

Authors:  Hannu Kokki; Ilpo Rasanen; Merja Lasalmi; Sanna Lehtola; Veli-Pekka Ranta; Kari Vanamo; Ilkka Ojanperä
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Morphine mouthwashes for painful mucositis.

Authors:  Leandro Cerchietti
Journal:  Support Care Cancer       Date:  2006-08-15       Impact factor: 3.603

3.  Assessment of indomethacin oral spray for the treatment of oropharyngeal mucositis-induced pain during anticancer therapy.

Authors:  Kenji Momo; Hiroka Nagaoka; Yoshiyuki Kizawa; Hiroki Bukawa; Shigeru Chiba; Yukinao Kohda; Masato Homma
Journal:  Support Care Cancer       Date:  2017-07-15       Impact factor: 3.603

Review 4.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 6.  Clinical pharmacokinetics of drug administered buccally and sublingually.

Authors:  J G Motwani; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

7.  Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.

Authors:  Kelly E Dunn; Frederick S Barrett; George E Bigelow
Journal:  Addict Behav       Date:  2018-03-28       Impact factor: 3.913

8.  Development of a GC-MS assay for the determination of fentanyl pharmacokinetics in rabbit plasma after sublingual spray delivery.

Authors:  Ahmad H Malkawi; Abeer M Al-Ghananeem; Peter A Crooks
Journal:  AAPS J       Date:  2008-05-06       Impact factor: 4.009

9.  Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Authors:  Debra S Harris; John E Mendelson; Emil T Lin; Robert A Upton; Reese T Jones
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 10.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.